

**ADRENOCORTICAL CARCINOMA****Mandava Mahima Swaroopa\*, Chinnam Sri Varsha, Pulimala Saranya Raj and Sajja Sai Premika**

KVSR Siddhartha Pharmacy College, Vijayawada, Andhra Pradesh, India. 520001.

Received on: 01/03/2020

Revised on: 21/03/2020

Accepted on: 11/04/2020

\*Corresponding Author

Mandava Mahima

Swaroopa

KVSR Siddhartha Pharmacy  
College, Vijayawada, Andhra  
Pradesh, India. 520001.**ABSTRACT**

**Background:** ACC seems to be commonest within the fourth and fifth decades in life, though there's a second peak in infancy, probably associated with genetic predisposition syndromes. Adrenocortical tumors are divided into benign and malignant teams, either hormonally silent or internally secreting. ACC enters through Mono-clonality which indicates that growth progression is the effect of associate intrinsic mutation, whereas polyclonality suggests that growth cells are plagued by native or general stimuli. Ras proteins, a layer related proteins which are associated with downstream flagging, when ligand incitement of receptor happens. X-ray gives data about the intrusion of an adrenocortical carcinoma into veins, especially the second rate vena cava, the adrenal and renal veins, in which tumor thrombi might be recognized sometimes.

**KEYWORDS:** (ACC) Adrenocortical Carcinoma (APC) Adenomatous Polyposis Coli (APC) Adenomatous polyposis coli protein.

**INTRODUCTION**

Cortex cancer (ACC, adrenal animal tissue cancer, adrenal animal tissue cancer, endocrine cancer, etc.) is associate aggressive cancer originating within the cortex (steroid hormone-producing tissue) of the adrenal. Cortex cancer could be a rare tumour, with incidence of 1–2 per million population annually though rare, ACC is aggressive, because it accounts for between zero.04 and 0.2 % of all cancer deaths with a moderate feminine predominance. ACC seems to be commonest within the fourth and fifth decades in life, though there's a second peak in infancy, probably associated with genetic predisposition syndromes like Li-Fraumeni Syndrome and Beckwith-Wiedemann Syndrome. The unwellness in young kids appears to behave otherwise compared with adults, as medicine tumors ar rather more usually steroid hormone manufacturing tumors and therefore the prognosis is best. ACCs ar most typically staged by the factors developed by the ecu Network for the Study of Adrenal Tumors beneath these criteria, regarding thirty fifth of patients gift with adrenal unwellness solely (stage I and II), eighteen with domestically invasive unwellness (stage III), and forty seventh with pathologic process unwellness (stage IV). The 5-year cancer specific mortality-free survival rates ar about seventy four (Stage I), sixty fourth (Stage II), a quarter mile (Stage III), and seven (Stage IV) within the North yank expertise, indicating the pressing would like for general therapies. Between sixty and seventieth of adult ACCs ar humor tumors, and patients with humor tumors tend to own a rather worse prognosis. For a additional thorough discussion of the overall topic of ACC, readers ar brought up variety of fantastic recent reviews.<sup>[1,2]</sup>

**Classification**

Adrenocortical tumors are divided into benign and malignant teams. Either will be hormonally silent or internal secretion secreting. The overwhelming majority of endocrine gland tumors are benign and hormonally silent.<sup>[3,4]</sup>

The hormone-secreting tumors will turn out glucocorticoids, androgens, mineralocorticoids, estrogens, and combos thence.<sup>[3,8,5]</sup>

**Pathophysiology of Endocrine Gland Cancer**

The analysis of growth clonality is a vital step to ascertain the cellular origin of neoplasms and to spot the mechanisms underlying growth progression. Mono-clonality indicates that growth progression is that the effect of associate intrinsic mutation, whereas polyclonality suggests that growth cells are plagued by native or general stimuli. Analysis of the pattern of X-chromosome inactivation in heterozygous feminine tissue has shown that Air Combat Command consists of organism populations of cells, whereas benign tumors can be organism yet as polyclonal (Monoclonal tumors result from genetic alterations conferring a growth advantage to the cell at the start affected. These genetic events will be studied at the size of the entire ordination, as losses or gains of half or all of a body.<sup>[6]</sup>

An outsized range of molecular techniques, like comparative genomic crossing (CGH) and microsatellite analysis, will be utilized ingenome-wide screen for such body alterations. These approaches have known alterations touching varied chromosomes and loci. Apparently, a correlation has been determined between

growth size and also the range of CGH changes in endocrine gland tumors, suggesting that body alterations accumulate throughout growth progression.<sup>[7]</sup>

it had been incontestable by CGH that body alterations are determined in twenty eight of benign endocrine gland tumors. Most of the changes determined concern losses on chromosomes two, 11q and 17p and gains on chromosomes four and five.<sup>[8,9]</sup>

In additional recent studies, CGH known changes in sixty one of benign tumors and also the most typical gains determined were on chromosomes five, 12, 19. Losses were determined at 1p, 17p, 22p, 22q, 2q, and 11q in up to sixty two of cases of Air Combat Command. Studies victimisation microsatellite markers have incontestable a high proportion of loss of state (LOH) or allelomorph imbalance at 11q13 ( $\geq 90\%$ ), 17p13 ( $\geq 85\%$ ), and 2p16 (92%) in Air Combat Command.

The genes concerned in these molecular alterations might be classified as growth suppressor genes on one hand, and oncogenes on the opposite hand. Molecular alterations would result in inactivation of the growth suppressor genes and activation of the oncogenes. This is easy thanks to classify the varied alterations concerned in oncogenesis are utilized in this paragraph to review the pathophysiology of Air Combat Command.


### B-CATENIN ACTUATION IN ACC

Hereditary adjustments of the Wnt flagging pathway were at first distinguished in familial adenomatous polyposis coli and have been reached out to an assortment of malignant growths.<sup>[16]</sup>

Adrenocortical tumors have been seen for some situation reports of patients with familial adenomatous polyposis coli.<sup>[17]</sup>

Moreover, familial adenomatous polyposis coli patients with germline transformations of the APC (Adenomatous Polyposis Coli) quality that prompt an enactment of the Wnt flagging pathway, may create ACTs (18). Atomic examinations have recommended that physical changes of APC could happen in these tumors in patients as of now having a germline deformity.

The Wnt flagging pathway is regularly initiated amid embryonic advancement.  $\beta$ -Catenin is a key segment of flagging pathway.



It has an auxiliary job in cell– cell grip, and is a translation cofactor with T-cell factor/lymphoid enhancer factor (TCF/LEF) interceding transcriptional actuation of target qualities of the Wnt flagging pathway. Curiously, quality profiling considers in different kinds of adrenocortical tumors have demonstrated the continuous initiation of Wnt flagging target qualities: in ACC, a microarray approach has demonstrated that ectodermal-neural cortex-1 (ECN-1) was up-directed. In both generous and threatening ACT,  $\beta$ -catenin aggregation can be watched. These modifications appear to be exceptionally visit in ACC, steady with a strange actuation of the Wnt-flagging pathway. This is clarified in a subset of adrenocortical tumors by physical transformations of the  $\beta$ -catenin quality changing the glycogen synthase kinase 3- $\beta$  (GSK3- $\beta$ ) phosphorylation site.<sup>[19]</sup> GSK3- $\beta$  is ensnared in the control of  $\beta$ -catenin. Without Wnt flagging, the level of  $\beta$ -catenin is low:  $\beta$ -catenin is phosphorylated at basic NH<sub>2</sub>-terminal deposits by the GSK3- $\beta$  bound to a platform complex of axin and adenomatous polyposis coli protein (APC) and therefore the phosphorylated protein is corrupted by the ubiquitin–proteasome framework. Wnt incitement prompts the inactivation of GSK3- $\beta$  and in this way the adjustment of  $\beta$ -catenin in the cytoplasm.

### Ras Oncogene

Ras proteins are layer related proteins associated with downstream flagging, when ligand incitement of development factor receptor happens. The three ras proteins (H, N, and K) are a standout amongst the most regularly transformed oncogenes in human diseases. Disputable information are available in the.<sup>[20]</sup> K-ras changes in about half of tumor tissues of Conn's adenomas and no transformations are seen in H-ras,<sup>[21]</sup> did not recognize Ras transformations.

### Development Factors

Different development components and cytokines other than IGFs have been appeared to direct adrenal development and capacity in typical grown-up and fetal

adrenals. These incorporate essential fibroblast development factor (FGF-2), changing development factor- $\alpha$  (TGF- $\alpha$ ) and changing development factor- $\beta$ 1 (TGF- $\beta$ 1), vascular endothelial development factor (VEGF), and interleukins.<sup>[22]</sup> Among these elements, FGF-2 might be a prime possibility to assess in adrenocortical tumors. This development factor is exceptionally communicated in adrenal tissues and is a standout amongst the most powerful mitogens in cell culture of grown-up and fetal adrenal. In human fetal adrenal organs, mitogenic impact of IGF-II and FGF-2 is mitogenic for the H295R cells, controls the declaration of both IGF-II and IGFBP-2, and balances the preparing of genius IGF-II.

Angiogenesis assumes a noteworthy job in disease development and metastasis. The angiogenic status of a tumor can be evaluated by the investigation of VEGF articulation. In ACC, an overexpression of VEGF by correlation with adrenal adenomas. However, a separation between a high articulation of VEGF and a low vascularization was seen in ACC, recommending a separation between the angiogenic status and the neoangiogenic abilities of these tumors. Very curiously, serum VEGF levels were essentially higher in patients with ACC than in patients with adrenal adenomas and ordinary subjects. Although a critical decrease of serum VEGF levels multi month after medical procedure of ACC has been accounted for, its utilization as a tumor marker stays to be researched.

Changing development factor- $\beta$ 1 (TGF- $\beta$ 1), another multifunctional development modulator, restrains the expansion of epithelial cells and controls grown-up and fetal adrenal development and capacities. Two unique investigations exhibited a decreased TGF- $\beta$ 1 mRNA articulation in ACC, while no distinction in the articulation (nor transformation) of TGF- $\beta$ 1 receptor were seen in ACC.

### Imaging Procedures

The conclusion of adrenal neoplasm relies upon the ID of an adrenal mass on CT and additionally MRI. Both typical and strange adrenal organs are effectively noticeable on CT in light of the fat tissue that encompasses these organs in the retro peritoneum.<sup>[23]</sup>

CT gives data about size, homogeneity, nearness of calcifications, zones of rot, and degree of nearby attack, in this way additionally being useful in settling on choices about the resectability of the injury. Tumors as little as 0.5 cm have been distinguished by CT, in spite of the fact that the overall absence of retroperitoneal fat in kids may diminish the affectability of the test in this age gathering.

Regardless of whether MRI will end up being better than CT checking in diagnosing and separating adrenal masses stays to be seen. X-ray gives data about the intrusion of an adrenocortical carcinoma into veins,

especially the second rate vena cava and the adrenal and renal veins, in which tumor thrombi might be recognized sometimes. Studies have announced that MRI can recognize with a reasonable level of precision among essential harmful adrenocortical tumors, nonfunctioning adenomas, and pheochromocytomas by contrasting the proportion of the flag power of each kind of adrenal mass to that of liver.

In this way, essential dangerous adrenocortical sores have a halfway to high flag power on T2-weighted pictures. Nonfunctional adenomas have low flag force.

Early analysis and administration of adrenal tumors has experienced a noteworthy change with the advances in biochemical assessment, demonstrative imaging methods, and advancement in the field of negligibly intrusive medical procedure. Fitting appraisal of an adrenal mass is a fundamental essential before its authoritative treatment. An adrenal mass, which is out of the blue recognized through an imaging method performed for reasons inconsequential to adrenal brokenness or suspected brokenness is known as adrenal incidentaloma.<sup>[24]</sup>

Albeit uncommon, ACC is forceful, as it represents somewhere in the range of 0.04 and 0.2 percent of all disease passings with a moderate female prevalence. ACC seems, by all accounts, to be most regular in the fourth and fifth decades throughout everyday life, in spite of the fact that there is a second top in early youth, likely identified with hereditary inclination disorders, for example, Li-Fraumeni Syndrome and Beckwith-Weidman Syndrome. The malady in youthful youngsters appears to carry on diversely contrasted and grown-ups, as pediatric tumors are significantly more regularly androgen creating tumors and the visualization is better. ACCs are most usually organized by the criteria created by the European Network for the Study of Adrenal Tumors. Under these criteria, about 35% of patients present with adrenal illness just (arrange I and II), 18% with locally obtrusive ailment (arrange III), and 47% with metastatic ailment (organize IV). The 5-year malignant growth particular sans mortality survival rates are around 74% (Stage I), 64% (Stage II), 44% (Stage III), and 7% (Stage IV) in the North American experience, showing the squeezing requirement for foundational treatments. Somewhere in the range of 60 and 70% of grown-up ACCs are secretory tumors, and patients with secretory tumors will in general have a marginally more regrettable visualization. For a more exhaustive talk of the general theme of ACC, perusers are alluded to various phenomenal late audits.<sup>[25,26]</sup>

On imaging examines, PAL ordinarily displays as a substantial mass in which cystic or hemorrhagic segments might be available. Homogeneous and heterogeneous injuries are accounted for in comparable frequencies. Diffuse substantial cell B cell lymphoma is the most normally detailed subtype, anaplastic huge cell

or T-cell lymphoma are just announced sporadically.<sup>[27,28,29]</sup>

Anticipation depends intensely on treatment reaction, however a mean in general survival of 15 months has been accounted for.<sup>[30]</sup>

Early analysis and administration of adrenal tumors has experienced a noteworthy change with the advances in biochemical assessment, symptomatic imaging methods, and advancement in the field of insignificantly obtrusive medical procedure. Fitting appraisal of an adrenal mass is a basic essential before its authoritative treatment. An adrenal mass, which is out of the blue distinguished through and imaging methodology performed for reasons inconsequential to adrenal brokenness or suspected brokenness is known as adrenal incidentaloma.<sup>[31]</sup>

Its commonness at post-mortem ranges from 1.4% to 2.9%. Screening with ultrasound distinguishes incidentalomas in 0.1% populace with general great wellbeing. Maturing is related with expanded recurrence, commonness being <1% among people under 30 years old to about 7% in those more than 70 years of age.<sup>[32]</sup>

While treating adrenal tumors it ought to be recalled that the cortex and the medulla have diverse embryonic beginning and likewise have distinctive structure and work and create diverse tumors. It ought to likewise be borne as a main priority that tumors shift in their practical status. The occurrence of harm increments with the expansion in size of the tumor. With the future expanding, more adrenal masses are probably going to be distinguished unexpectedly; henceforth, thinks about with a long follow-up are expected to create rules for the proper administration of these tumors. The best imaging methodology for assessment of an adrenal mass is the difference improved figured tomography (CECT) filter. Perinephric fat enables the organ to be plainly shown and even 1 cm measure tumors can be distinguished with 100% sensitivity.<sup>[33]</sup>

### Imaging Procedures

The analysis of adrenal neoplasm relies upon the distinguishing proof of an adrenal mass on CT as well as MRI. Both ordinary and unusual adrenal organs are effortlessly obvious on CT as a result of the fat tissue that encompasses these organs in the retro peritoneum.<sup>[34]</sup>

CT gives data about size, homogeneity, nearness of calcifications, regions of rot, and degree of neighborhood attack, in this way additionally being useful in settling on choices about the resectability of the injury. Tumors as little as 0.5 cm have been recognized by CT, despite the fact that the overall absence of retroperitoneal fat in youngsters may diminish the affectability of the test in this age gathering.

Regardless of whether MRI will turn out to be better than CT filtering in diagnosing and separating adrenal masses

stays to be seen. X-ray gives data about the attack of an adrenocortical carcinoma into veins, especially the substandard vena cava and the adrenal and renal veins, in which tumor thrombi might be distinguished periodically. Studies have announced that MRI can recognize with a reasonable level of precision among essential threatening adrenocortical tumors, nonfunctioning adenomas, and pheochromocytomas by looking at the proportion of the flag force of each kind of adrenal mass to that of liver.

Accordingly, essential harmful adrenocortical injuries have a moderate to high flag power on T2-weighted pictures. Nonfunctional adenomas have low flag intensity<sup>35</sup>

### Pathology, Staging, and Prognosis

Histologically, adrenocortical tumors comprise of lipid-exhausted cells with granular cytoplasm and huge numerous cores and nucleoli.<sup>[36]</sup>

Tumor cells have shifting mitotic action. The separation of favorable from dangerous adrenocortical neoplasms exclusively based on histological discoveries is troublesome, if certainly feasible.<sup>[37]</sup>

Along these lines, a few reports shown that patients whose operatively extracted tumors displayed histologically kindhearted highlights and in this way created neighborhood repeats or inaccessible metastases, though others, whose tumors had a minute appearance average of threat, lived tumorfree for a long time. A few naturally visible and minuscule criteria are all things considered used to characterize the threat of an adrenocortical tumor and to foresee its behavior.<sup>[38]</sup>

Perceptibly, a wet weight of in excess of 500 g, a terribly lobulated cut surface, the nearness of necrotic zones or potentially calcifications, and intratumor hemorrhages foresee harm. Minutely, engineering chaos, visit mitoses, stamped cell pleomorphism, atomic atypia and hyperchromasia, and in addition intrusion of the case propose harm. Strange DNA substance have been identified in adrenocortical carcinomas by stream cytometric DNA examination.<sup>[39,40]</sup>

Aneuploidy happens in neoplastic subpopulations through hereditary flimsiness and mitotic abnormalities. Bowlby *et al.* detailed that 83% of the carcinomas indicated aneuploidy, proposing that stream cytometric examination may end up being a supplement to the customary histopathological strategies and an important device in foreseeing the guess of patients with adrenocortical tumors.

### Relationship With Chromosomal Abnormalities And Genetic Syndromes

The likelihood that there is an acquired inclination to create adrenocortical tumors has been recently engaged.<sup>[41,42]</sup>

Adrenocortical carcinoma has been accounted for in kin, and a high occurrence of different malignancies has been noted in families and relatives of patients with adrenocortical carcinomas (20– 23). Likewise, high frequencies of inborn inconsistencies and optional tumors have been exhibited in patients with adrenal malignant growth.<sup>[43]</sup>

There are a few perceived hereditary disorders that have been related with adrenocortical neoplasms, Patients with the Li-Fraumeni disorder have a high occurrence of adrenocortical carcinomas Germline transformations in p53, situated on chromosome 17p, were distinguished in families with this disorder what's more, Yano et al. portrayed irregularities of chromosome 17 in adrenocortical carcinomas that were perfect with loss of heterozygosity and faulty tumor silencer action of p53, as was later shown in 27% of threatening adrenocortical tumors and two adrenocortical tumor cell lines inspected.<sup>[44,45]</sup>

### Treatment

Hormone-discharging adrenocortical tumors and hormon-partner quiet adrenal masses with a measurement of 5 cm or more, or littler masses with a suspicious imaging appearance ought to be.<sup>[2,3,47]</sup> Careful resection is likewise the main treatment for adrenocortical carcinoma that unques-tionably fixes or draws out survival altogether, especially if the infection is identified at stages I and II.<sup>[46,47]</sup>

Radical extraction with en coalition resection of any neighborhood intrusion offers the most obvious opportunity for fix. A wide presentation is required, utilizing an all-encompassing subcostal entry point or a thoracoabdominal approach (Patients clearly relieved with medical procedure require contin-ued observation. Mitotane after total plainly visible re-area in stage III and IV illness might be given to expand the period of time between repeats; be that as it may, this has not been tried in a controlled report.<sup>[48]</sup>

An astounding audit of the treatment of adrenal malignancy showed up as of late,<sup>[49]</sup> Mitotane has been utilized widely in patients with adre-nocortical carcinoma; in any case, this medication has been for the most part ineffectual in drawing out by and large survival in the propelled phases of the infection.<sup>[50,51]</sup> Mitotane goes about as an adrenolytic specialist, potentially by causing modifications in mitochondrial work, blocking adrenal steroid 11b-hydroxylation, and adjusting the extraadrenal digestion of cortisol and androgens. Concentrates shown that high oral dosages (up to 12– 14 g/day) of mi-totane caused reduction of hypercortisolism in 50– 60% of patients with adrenocortical carcinoma; nonetheless, 6– 10 monthlong, target tumor reactions happened in under 20% of these patients The symptoms of mitotane are to a great extent portion related. Shortcoming, drowsiness, perplexity, dormancy, and migraine are accounted for in half of the patients treated

Moreserious neurotoxicity, for example, ataxia and dysarthria, may likewise happen.<sup>[52]</sup> Gastrointestinal reactions incorporate anorexia, nausea, and looseness of the bowels, which are available in many patients. Skin rash, lethal retinopathy with papilledema, and interstitial cystitis are less generally observed. A few option chemotherapeutic regimens have been utilized for the treatment of metastatic adrenocortical carcinoma They incorporate cisplatin, etoposide, 5-fluorouracil, doxorubicin, vincristine, gossipol, suramin, and melphalan.<sup>[53,54]</sup> Gossipol, a spermatotoxin got from rough cottonseed oil, restrains the development of human adrenocortical tumors in naked mice. Oral gossipol (30– 70 mg/day) was utilized with relative security in out-patients with metastatic adrenal malignant growth; be that as it may, a half-way tumor reaction rate was seen in just 17%.<sup>[55]</sup>

This is reliable with the by and large poor reaction of adrenal disease to most medicinal treatments. Consolidating mitotane with cytotoxic chemotherapy has been related with constrained achievement. Different regimens have been accounted for, including those utilizing mitotane and 5-fluorouracil, cisplatin and etoposide, and cisplatin doxorubicin and 5-fluorouracil. Postulations examines have not demonstrated a noteworthy prolongation of survival, albeit some disengaged reports of drawn out or finish abatement were distributed.

### CONCLUSION

Cortex cancer is a rare tumour, with incidence of 1–2 per million population annually, ACC is aggressive, because it accounts for 0.04 and 0.2 % of all cancer deaths with a moderate feminine predominance. The analysis of adrenal neoplasm relies upon the distinguishing proof of an adrenal mass on CT as well as MRI. The(20)K-ras changes in about half of tumor tissues of Conn's adenomas and no transformations are seen in H-ras. The angiogenic status of a tumor can be evaluated by the investigation of VEGF articulation. Mitotane has been utilized widely in patients with adrenocortical carcinoma.

### REFERENCE

1. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. *Endocrine reviews*, 2014; 35(2): 282–326.
2. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. *J Clin Endocrinol Metab*, 2013; 98(12): 4551–4564.
3. Ross NS, Aron DC. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. *N Engl J Med*, 1990; 323: 1401–1405.
4. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. *Endocr Rev.*, 1995; 16: 460–483.

5. Flack MR, Chrousos GP. Neoplasms of the adrenal cortex. In: Holland R, ed. *Cancer Medicine*, 4th ed. New York: Lea and Fibinger, 1996; 1563–1570.
6. Favia G. Adrenocortical carcinoma: is prognosis different in nonfunctioning tumors? Results of surgical treatment in 31 patients. *World Journal of Surgery*, 2001; 25:735–738.
7. Sidhu S *et al.* Comparative genomic hybridization analysis of adrenocortical tumors. *Journal of Clinical Endocrinology and Metabolism*, 2002; 87:3467–3474.
8. Kolomecki K. Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours. *Cytobios*, 2000; 101:55–64.
9. Dohna M. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. *Cancer*, 2000; 88:145–152.
10. Hotta M & Baird A. Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro. *PNAS*, 1986; 83:7795–7799.
11. Lam WW. Analysis of germline CDKN1C (p57kip2) mutations in familial and sporadic Beckwith–Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. *Journal of Medical Genetics*, 1999; 36:518–523.
12. Wiedemann HR. Tumours and hemihypertrophy associated with Wiedemann–Beckwith syndrome. *European Journal of Pediatrics*, 1983; 141:129.
13. Mesiano S. Basic fibroblast growth factor expression is regulated by corticotropin in the human fetal adrenal: a model for adrenal growth regulation. *PNAS* 88:5428–5432, 1991.
14. Ilvesmaki V. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. *Journal of Clinical Endocrinology and Metabolism*, 1993; 77:852–858.
15. Giordano TJ *et al.* Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. *American Journal of Pathology*, 2003; 162:521–531.
16. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. *Cancer Science*, 2003; 94:225–229.
17. Naylor EW & Gardner EJ. Adrenal adenomas in a patient with Gardner's syndrome. *Clinical Genetics*, 1981; 20:67–73.
18. Blaker H. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. *Cancer*, 2004; 94:93–98.
19. Tissier F *et al.* Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. *Cancer Research*, 2005; 65:7622–7627.
20. Gicquel C *et al.* Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. *Cancer Research* 61:6762–6767, 2001.
21. Ocker M. PCR-SSCP analysis of human adrenocortical adenomas: absence of K-ras gene mutations. *Experimental and Clinical Endocrinology and Diabetes* 108:513–514.
22. Hutter AM Jr & Kayhoe DE. *American Journal of Medicine*, 1966; 41:581–592.
23. Shapiro B, Fig LM, Gross MD, Khafagi F. Contributions of nuclear endocrinology to the diagnosis of adrenal tumors. *Recent Results Cancer Res.*, 1990; 118: 113–138.
24. Cohn K, Gottesman L, Brennan M. Adrenocortical carcinoma. *Surgery*, 1986; 100: 1170–7.
25. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, *et al.* Adrenocortical carcinoma. *Endocrine reviews*, 2014; 35(2): 282–326.
26. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. *J Clin Endocrinol Metab*, 2013; 98(12): 4551–4564.
27. Grigg A. P., Connors J. M. Primary adrenal lymphoma. *Clinical Lymphoma*, 2003; 4(3): 154–160. doi: 10.3816/CLM.2003.n.024.
28. Ozimek A., Diebold J., Linke R., Heyn J., Hallfeldt K., Mussack T. Bilateral primary adrenal non-Hodgkin's lymphoma and primary adrenocortical carcinoma—review of the literature preoperative differentiation of adrenal tumors. *Endocrine Journal*, 2008; 55(4): 625–638. doi: 29.1507/endocrj.K08E-035.
29. Schnitzer B., Smid D., Lloyd R. V. Primary T-cell lymphoma of the adrenal glands with adrenal insufficiency. *Human Pathology*, 1986; 17(6): 634–636. doi: 10.1016/S0046-8177(86)80136-8.
30. Ozimek A., Diebold J., Linke R., Heyn J., Hallfeldt K. K. J., Mussack T. Bilateral primary adrenal non-hodgkin's lymphoma—a case report and review of the literature. *European Journal of Medical Research*, 2008; 13(5): 221–228.
31. Cohn K, Gottesman L, Brennan M. Adrenocortical carcinoma. *Surgery*, 1986; 100: 1170–7.
32. Aron D, Terzolo M, Cawood TJ. Adrenal incidentalomas. *Best Pract Res Clin Endocrinol Metab*, 2012; 26: 69–82.
33. Khanna R, Khanna S, Bhadani S, Sharma AD, Basu SP. Hemorrhagic nonfunctioning adrenal cyst: Case report with review of literature. *J Surg Sci.*, 2011; 2: 29–30.
34. Shapiro B, Fig LM, Gross MD, Khafagi F. Contributions of nuclear endocrinology to the diagnosis of adrenal tumors. *Recent Results Cancer Res.*, 1990; 118: 113–138.
35. Shapiro B, Fig LM, Gross MD, Khafagi F. Contributions of nuclear endocrinology to the diagnosis of adrenal tumors. *Recent Results Cancer Res.*, 1990; 118: 113–138.

36. Barzilay JI, Pazianos AG. Adrenocortical carcinoma. *Urol Clin North Am*, 1989; 16: 457–468.
37. Mendonca BB, Lucon AM, Menezes CAV, et al. Clinical, hormonal and pathological findings in a comparative study of adrenal cortical neoplasms in childhood and adulthood. *J Urol*. 154:2004–2009. 6. Luton JP, Cerdas S, Billaud L, et al. 1990 Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. *N Engl J Med*, 1995; 322: 1195–1201.
38. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. *Am J Surg Pathol*, 1984; 8: 163–169.
39. Bowlby LS, DeBault L, Abraham SR. Flow cytometric analysis of adrenal cortical tumor DNA. *Cancer*, 1986; 58: 1499–1505.
40. Taylor S, Roederer M, Murphy R. Flow cytometric DNA analysis of adrenocortical tumors in children. *Cancer*, 1987; 59: 2059–2063.
41. Ping AP, Reeve AE, Law DJ, Young MR, Boehnke M, Feinberg AP. Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. *Am J Hum Genet.*, 1989; 44: 720–723.
42. Rosenberg C, Della-Rosa VA, Latronico AC, Mendonca BB, Vianna-Morgante AM. Selection of adrenal tumor cells in culture demonstrated by interphase cytogenetics. *Cancer Genet Cytogenet.*, 1995; 79: 36–40.
43. Gicquel C, Xavier B, Schneid H, et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adreno-cortical tumors. *J Clin Endocrinol Metab.*, 1994; 78: 1444–1453.
44. Yano T, Linehan M, Anglard P, et al. Genetic changes in human adrenocortical carcinoma. *J Natl Cancer Inst.*, 1989; 81: 518–523.
45. Gicquel C, Bertagna X, Bouc YL. Recent advances in the pathogenesis of adrenocortical tumours. *Eur J Endocrinol*, 1995; 133: 133–144.
46. Barzilay JI, Pazianos AG. Adrenocortical carcinoma. *Urol Clin North Am*, 1989; 16: 457–468.
47. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. *Surgery*, 1992; 112: 963–971.
48. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. *N Engl J Med*, 1990; 322: 1195–120.
49. Schteingart DE. Treating adrenal cancer. *Endocrinologist.*, 1992; 2: 149–157.
50. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. *N Engl J Med.*, 1990; 322: 1195–1201.
51. Schteingart DE. Treating adrenal cancer. *Endocrinologist*, 1992; 2: 149–157.
52. Barzilay JI, Pazianos AG. Adrenocortical carcinoma. *Urol Clin North Am.*, 1989; 16: 457-468.
53. Flack MR, Pyle RG, Mullen NM, et al. Oral gossypol in the treatment of metastatic adrenal cancer. *J Clin Endocrinol Metab*, 1993; 76: 1019–1024.
54. Schlumberger M, Ostronoff M, Bellaiche M, Rougier P, Droz JP, Parmentier C. 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. *Cancer*, 1988; 61: 1492–1494.